Evidence map›Paper›PMID 33319058›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2020

Hepascore predicts liver outcomes and all-cause mortality in long-term methotrexate users: A retrospective cohort study.

Zhengyi Wang, Yi Huang, Hans Nossent, Jonathan J Chan, Leon A Adams, John Joseph, Wendy Cheng, George Garas, Gerry MacQuillan, Gary P Jeffrey

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Zhengyi WangSchool of Medicine and Pharmacology The University of Western Australia Perth Western Australia Australia.ORCID https://orcid.org/0000-0002-1738-2207
Yi HuangSchool of Medicine and Pharmacology The University of Western Australia Perth Western Australia Australia.ORCID https://orcid.org/0000-0003-0853-9468
Hans NossentSchool of Medicine and Pharmacology The University of Western Australia Perth Western Australia Australia.
Jonathan J ChanDepartment of Dermatology Sir Charles Gairdner Hospital Perth Western Australia Australia.
Leon A AdamsSchool of Medicine and Pharmacology The University of Western Australia Perth Western Australia Australia.
John JosephDepartment of Biochemistry PathWest Laboratory Medicine Perth Western Australia Australia.
Wendy ChengDepartment of Gastroenterology and Hepatology Royal Perth Hospital Perth Western Australia Australia.
George GarasDepartment of Hepatology Sir Charles Gairdner Hospital Perth Western Australia Australia.
Gerry MacQuillanSchool of Medicine and Pharmacology The University of Western Australia Perth Western Australia Australia.
Gary P JeffreySchool of Medicine and Pharmacology The University of Western Australia Perth Western Australia Australia.
The University of Western Australia · AUSir Charles Gairdner Hospital · AUPathwest Laboratory Medicine · AURoyal Perth Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimMethotrexate (MTX) is routinely used for immunological disorders, and its long-term use is associated with hepatotoxicity. The aim of this study was to investigate whether a serum liver fibrosis test (Hepascore) predicted the risk of adverse liver-related outcomes and mortality.

methodsA total of 92 patients in Western Australia who had a long-term MTX intake history,from 2004 to 2016, were recruited and followed up from the first Hepascore to death or end of the study. Clinical data, all deaths, and liver-related outcomes (liver-related death and decompensation) were obtained from hospital, PathWest, and WA Data Linkage Unit databases.

resultsNine deaths and four adverse liver-related outcomes occurred during the follow up of 354 person-years. The 5-year survival was 86.1%. The liver-related outcome free survival was 95.6%. Baseline Hepascore ≥0.84 was associated with advanced fibrosis on liver biopsy (

conclusionsThis study demonstrated the potential importance of Hepascore monitoring in long-term MTX users. Patients with a Hepascore higher than 0.84 at any stage had increased mortality, but further studies are required to confirm this finding.

Indexed as

all‐cause mortalitydecompensationHepascorehepatotoxicitymethotrexate

Identifiers

PMID33319058
PMCPMC7731826
OpenAlexW3094410220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.